

# NANOPORE SEQUENCING FINDS NOVEL REGULATORY ABO VARIANT CAUSING MIXED-FIELD AGGLUTINATION IN AB DONOR

GA Thun<sup>1</sup>, M Gueuning<sup>1</sup>, S Sigurdardottir<sup>2</sup>, E Meyer<sup>2</sup>, E Gourri<sup>1,2</sup>, L Schneider<sup>2</sup>, C Engström<sup>3</sup>, J Sigle<sup>4</sup>, BM Frey<sup>1,2,3</sup>, S Meyer<sup>2\*</sup>, MP Mattle-Greminger<sup>1\*</sup>

<sup>1</sup>Department of Research and Development, <sup>2</sup>Department of Molecular Diagnostics and Cytometry, <sup>3</sup>Department of Immunohematology, Blood Transfusion Service Zurich, Schlieren, Switzerland

<sup>4</sup>Blood Transfusion Centre Aargau-Solothurn (SRC), Aarau, Switzerland

\* equal contribution

www.blutspendezurich.ch




## Background

- Mixed-field agglutination in ABO phenotyping (e.g. A<sub>3</sub>/B<sub>3</sub>) often linked to variants in ABO exon 7 and regulatory regions<sup>1-3</sup>
- Very limited knowledge on genetic diversity in regulatory regions because rarely sequenced
- Haplotype-resolved long-read sequencing with great potential to explain cryptic ABO phenotypes
- Proof of concept: nanopore sequencing to resolve a case of mixed-field agglutination in ABO forward typing

## Methods

- ABO serology, including anti-A1 and anti-H specific agglutination (Fig. 1a)
- ABO genotyping using PCR-SSP
- Flow cytometry: A-, B-, and H-antigen expression (Fig. 1a)
- Exclusion of chimerism using digital PCR
- Nanopore sequencing of entire ABO gene → 2 overlapping long-range PCR products (~13 kb each)
- Variant confirmation by Sanger sequencing
- Germline vs. somatic origin discriminated by analyzing donor's mother and brother



**Fig 1. (a)** Serological and flow cytometry results for donor, her mother and brother. **(b)** Alignment of ABO reference (NG\_006669.2) and nanopore-based haplotype sequences showing novel variant in RUNX1 binding site in intron 1 (+5.8 kb site) on ABO\*A allele of donor. Same SNV was found on the mother's ABO\*A allele. Sequence positions of previously reported RUNX1 variants linked to anti-A or anti-B mixed-field agglutination are highlighted in light green<sup>2,3</sup>.

## Results

- Mixed-field reaction with anti-A in donor genotyped as AB (Fig. 1a)
- Agglutination with anti-H was weak and absent with anti-A1
- Nanopore sequencing: novel variant (g.10924C>A) on the ABO\*A allele in a binding motif for the transcription factor Runt-related transcription factor 1 (RUNX1) (Fig. 1b)
- Germline SNV:
  - Mother (genotype: ABO\*A | ABO\*O.01; serology: mixed-field agglutination)
    - SNV in RUNX1 binding site of ABO\*A allele (Fig. 1b)
  - Brother (genotype: ABO\*O.01 | ABO\*O.01; serology: O)
    - No SNV in RUNX1 binding site

## Conclusions

- Discovery of a unknown SNV in RUNX1 binding motif causing an A<sub>3</sub> phenotype
- Extends current knowledge of four other variants<sup>2,3</sup> affecting this motif, all leading to A<sub>3</sub>/B<sub>3</sub> or A<sub>m</sub>/B<sub>m</sub> phenotypes
- Nanopore sequencing of long-range PCRs allowed haplotype generation of the entire ABO gene → This simplifies the crucial assessment of known and unknown regulatory regions in cases of complex antigen expression

## References

- ABO blood group alleles v1.1 21-OCT-2017 ISBT
- Ying et al. (2018). Vox Sanguinis, 113(6), 594-600
- Hult et al. (2020). Vox Sanguinis, 115(Suppl. 1), 15, 3A-S04-03

